ClinicalTrials.gg
CompletedNCT00191152Updated Dec 24, 2009Results posted

A Phase III Trial For Patients With Metastatic Breast Cancer

A Phase 3 interventional study of gemcitabine and docetaxel in Breast Cancer, Breast Neoplasms and Cancer of the Breast, sponsored by Eli Lilly and Company. Completed at 65 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-12-24.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
475
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.

Enrollment
5th of 90
475 · median 68
Started
2002
with 8 others
Phase 3
15 of 95
none open now
Registered
22nd of 95
by date
Lead sponsor
20 of 95
Eli Lilly and Company

Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 5th largest by enrollment of the 90 interventional ones that give a count, is one of 9 that started in 2002, is one of 15 in phase 3, and was the 22nd registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing gemcitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a phase III randomized study between the docetaxel/gemcitabine and docetaxel/ capecitabine doublets, with crossover to the alternate agent. The experimental arm will receive gemcitabine 1000 mg/m2 intravenous (IV) over 30 minutes days 1 and 8 and docetaxel 75 mg/m2 IV day 1 over 1 hour repeated every three weeks. The comparator arm will receive docetaxel 75 mgm/m2 IV day 1 over 1 hour and oral capecitabine 1000 mg/m2 twice daily, days 1 through 14 repeated every three weeks. Patients who progress on the experimental arm, will be treated with capecitabine as dosed on the comparator arm. Patients who progress on the comparator arm will be treated with gemcitabine as dosed on the experimental arm.

03

Conditions studied

  • Breast Cancer
  • Breast Neoplasms
  • Cancer of the Breast

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic or cytologic confirmation of breast cancer with locally advanced and/or disease
  • Patients may have received prior or adjuvant taxane regimen as long as it has been greater than or equal to 6 months since completion of the regimen
  • Patients may have had 0-1, but no more than one prior course of chemotherapy for metastatic disease
  • Patients must have either measurable or non-measurable (evaluable) disease
  • Prior radiation therapy allowed of less than 25% of the bone marrow

Exclusion criteria

Exclusion Criteria:

  • Second primary (except in situ carcinoma of the cervix or adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated at least 5 years previously with no evidence of recurrence)
  • Parenchymal or
  • Peripheral neuropathy greater than or equal to grade 2
  • Prior treatment with gemcitabine and capecitabine will not be allowed. Prior treatment with a taxane in the setting will not be allowed. Prior taxane therapy in the or adjuvant setting is allowed if completion of therapy greater than or equal to 6 months prior to enrollment.
  • Active cardiac disease not controlled by therapy and/or myocardial infarction within the preceding 6 months.
  • Concomitant Herceptin is not allowed
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
475 participants (actual)

Study arms

  • Experimental
    Gemcitabine + Docetaxel

    Drug: gemcitabine · Drug: docetaxel

  • Active comparator
    Capecitabine + Docetaxel

    Drug: docetaxel · Drug: capecitabine

Interventions

  • 1000 mg/m2, intravenous (IV) day 1 and day 8 every 21 days until disease progression

    Also known as: LY188011, Gemzar

  • 75 mg/m2, intravenous (IV), every 21 days until disease progression

  • 1000 mg/m2, by mouth (PO) twice a day (BID), days 1-14, every 21 days until disease progression

06

What researchers measure

Primary outcomes

  1. Time to Disease Progression (Initial Treatment)

    Time to disease progression (TTDP) at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression or the date of death due to disease under study, whichever came first. TTDP censored at earliest of: 1) date of death not due to disease; or 2) date of last contact for participants alive without disease progression; or 3) start date of other anti-tumor therapy; or 4) first dose date of crossover treatment.

    Time frame: Randomization date to the earliest date of first documented disease progression date or the date of death if the participant died due to study disease (up to 82 months)

Secondary outcomes

  1. Time to Disease Progression (Crossover Treatment)

    For crossover treatment, time to disease progression (TTDP) was defined as the number of months between the first dose date of crossover treatment and the date of disease progression or the date of death due to disease under study, whichever came first. TTDP for crossover treatment only applied to those participants who crossed over from initial treatment to crossover treatment. TTDP censored at earliest of: 1)date of death not due to disease; or 2)date of last contact for participants alive without disease progression; or 3)start date of other anti-tumor therapy due to progression.

    Time frame: Date of first dose of crossover treatment to date of first-documented disease progression after receiving first crossover treatment or date of death due to study disease, whichever came first (up to 82 months)

  2. Progression-Free Survival (Initial Treatment)

    For initial treatment, progression-free survival (PFS) was defined as the number of months between the date of randomization and the date of first documented disease progression or the date of death due to any cause, whichever came first. Time to PFS was censored at the earliest of: 1) date of last contact for participants alive without disease progression; or 2) start date of other anti-tumor therapy for progression; or 3) first dose date of crossover treatment.

    Time frame: Date of randomization until the date of first documented progression or date of death from any cause, whichever came first (up to 82 months)

  3. Progression-Free Survival (Crossover Treatment)

    For crossover treatment, progression-free survival (PFS) was defined as the number of months between first dose date of crossover treatment and date of documented disease progression or date of death due to any cause, whichever came first. PFS for crossover treatment only applied to those participants who crossed over from initial treatment to crossover treatment. PFS was censored at the earliest of: 1) date of last contact for participants alive without disease progression; or 2) start date of other anti-tumor therapy for participants with documented disease progression.

    Time frame: First dose date of crossover treatment to date of first-documented progression after receiving crossover treatment or date of death due to any cause, whichever came first (up to 82 months)

  4. Duration of Response (Initial Treatment)

    Among tumor responders, duration of tumor response was measured from the date of response (complete response \[CR\] or partial response \[PR\] until the first date of documented progression or death from any cause. Duration of response was censored at the earliest of: 1) date of last contact for participants alive without disease progression (DP); or 2) start date of other anti-tumor therapy for DP; or 3) dose date of crossover treatment.

    Time frame: Date of response (CR or PR) until the first date of documented progression or death from any cause (up to 82 months)

  5. Duration of Response (Crossover Treatment)

    At crossover treatment, duration of response was measured from the time criteria were met for complete response (CR) or partial response (PR), until first date that recurrent or progressive disease was objectively documented or date of death due to any cause, whichever came first. This definition only applied to those who crossed over \& achieved CR or PR in crossover treatment. Duration of response censored at earliest of: 1) date of last contact for those alive without disease progression; or 2) start date of other anti-tumor therapy for documented disease progression.

    Time frame: Date of CR or PR until first date of recurrent or progressive disease after receiving crossover treatment was objectively documented or date of date due to any cause, whichever came first (up to 82 months)

  6. Overall Survival

    Overall survival time was defined as the number of months between the date of randomization and the date of death due to any cause. The overall survival time was censored at the date of last contact for participants who were still alive.

    Time frame: Date of randomization to date of death from any cause (up to 82 months)

  7. Best Overall Response (Initial Treatment)

    Best overall response was the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response was assessed using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that did not meet above criteria.

    Time frame: Best response from start of treatment until disease progression/recurrence (up to 82 months)

  8. Best Overall Response (Crossover Treatment)

    Best overall response was the best response recorded from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response assessed using RECIST criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that did not meet above criteria.

    Time frame: Best response from start of treatment until disease progression/recurrence (up to 82 months)

  9. Summary of Changes in Karnofsky Performance Status (KPS) by Treatment (Initial Treatment)

    KPS ranges from 0 to 100, subdivided into three categories: incapacitated (0-40), self-care (50-70), and normal activity (80-100).

    Time frame: Baseline until crossover treatment began (up to 82 months)

  10. Summary of Changes in Karnofsky Performance Status (KPS) by Treatment (Crossover Treatment)

    KPS ranges from 0 to 100, subdivided into three categories: incapacitated (0-40), self-care (50-70), and normal activity (80-100).

    Time frame: First day of crossover treatment until end of crossover treatment at trial discontinuation (up to 82 moths)

  11. Summary of Changes in Rotterdam Symptom Checklist (RSCL) by Treatment (Initial Treatment)

    RSCL includes 4 scales to assess quality of life (QOL) endpoints: 1) a 23-item physical distress level with scale score ranges from 23 to 92 \[low score represents better QOL\] 2)a 7-item psychological distress level with scale score ranges from 7 to 28\[low score represents better QOL\] 3)8-item activity level with scale score ranges from 8 to 32 \[high score represents better QOL\]; 1-item overall valuation of life with score range from 1 to 7 \[low score represents better QOL\].

    Time frame: Baseline until crossover treatment began (up to 82 months)

  12. Summary of Changes in Rotterdam Symptom Checklist by Treatment (Crossover Treatment)

    RSCL includes 4 scales to assess quality of life (QOL) endpoints: 1) a 23-item physical distress level with scale score ranges from 23 to 92 \[low score represents better QOL\] 2)a 7-item psychological distress level with scale score ranges from 7 to 28\[low score represents better QOL\] 3)8-item activity level with scale score ranges from 8 to 32 \[high score represents better QOL\]; 1-item overall valuation of life with score range from 1 to 7 \[low score represents better QOL\].

    Time frame: First day of crossover treatment until end of crossover treatment at trial discontinuation (up to 82 months)

07

Results

Posted Dec 8, 2009

Participant flow

Initial Treatment
Participant flow — Initial Treatment
MilestoneGemcitabine Plus DocetaxelDocetaxel Plus Capecitabine
Started239236
Received initial treatment236227
Completed9883
Not completed141153
Withdrew: Adverse event4367
Withdrew: Physician decision4031
Withdrew: Withdrawal by subject4028
Withdrew: Lost to follow-up06
Withdrew: Other1821
Crossover Treatment
Participant flow — Crossover Treatment
MilestoneGemcitabine Plus DocetaxelDocetaxel Plus Capecitabine
Started7781
Received treatment7680
Completed5053
Not completed2728
Withdrew: Adverse event88
Withdrew: Physician decision77
Withdrew: Withdrawal by subject69
Withdrew: Lost to follow-up21
Withdrew: Other43

Outcome measures

SecondaryTime to Disease Progression (Crossover Treatment)

For crossover treatment, time to disease progression (TTDP) was defined as the number of months between the first dose date of crossover treatment and the date of disease progression or the date of death due to disease under study, whichever came first. TTDP for crossover treatment only applied to those participants who crossed over from initial treatment to crossover treatment. TTDP censored at earliest of: 1)date of death not due to disease; or 2)date of last contact for participants alive without disease progression; or 3)start date of other anti-tumor therapy due to progression.

Time frame:
Date of first dose of crossover treatment to date of first-documented disease progression after receiving first crossover treatment or date of death due to study disease, whichever came first (up to 82 months)
Reported as:
Median · months
Time to Disease Progression (Crossover Treatment)
monthsCapecitabineGemcitabine
Time to Disease Progression (Crossover Treatment)4.51 (2.11 to 7.80)2.34 (2.04 to 3.78)
Statistical analysis
  • Capecitabine vs Gemcitabine · Log Rank · p = 0.145
SecondaryProgression-Free Survival (Initial Treatment)

For initial treatment, progression-free survival (PFS) was defined as the number of months between the date of randomization and the date of first documented disease progression or the date of death due to any cause, whichever came first. Time to PFS was censored at the earliest of: 1) date of last contact for participants alive without disease progression; or 2) start date of other anti-tumor therapy for progression; or 3) first dose date of crossover treatment.

Time frame:
Date of randomization until the date of first documented progression or date of death from any cause, whichever came first (up to 82 months)
Reported as:
Median · months
Progression-Free Survival (Initial Treatment)
monthsGemcitabine Plus DocetaxelDocetaxel Plus Capecitabine
Progression-Free Survival (Initial Treatment)9.01 (7.73 to 10.53)8.88 (7.27 to 10.89)
Statistical analysis
  • Gemcitabine Plus Docetaxel vs Docetaxel Plus Capecitabine · Log Rank · p = 0.361
SecondaryProgression-Free Survival (Crossover Treatment)

For crossover treatment, progression-free survival (PFS) was defined as the number of months between first dose date of crossover treatment and date of documented disease progression or date of death due to any cause, whichever came first. PFS for crossover treatment only applied to those participants who crossed over from initial treatment to crossover treatment. PFS was censored at the earliest of: 1) date of last contact for participants alive without disease progression; or 2) start date of other anti-tumor therapy for participants with documented disease progression.

Time frame:
First dose date of crossover treatment to date of first-documented progression after receiving crossover treatment or date of death due to any cause, whichever came first (up to 82 months)
Reported as:
Median · months
Progression-Free Survival (Crossover Treatment)
monthsCapecitabineGemcitabine
Progression-Free Survival (Crossover Treatment)4.51 (2.11 to 7.80)2.34 (2.04 to 3.78)
Statistical analysis
  • Capecitabine vs Gemcitabine · Log Rank · p = 0.145
PrimaryTime to Disease Progression (Initial Treatment)

Time to disease progression (TTDP) at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression or the date of death due to disease under study, whichever came first. TTDP censored at earliest of: 1) date of death not due to disease; or 2) date of last contact for participants alive without disease progression; or 3) start date of other anti-tumor therapy; or 4) first dose date of crossover treatment.

Time frame:
Randomization date to the earliest date of first documented disease progression date or the date of death if the participant died due to study disease (up to 82 months)
Reported as:
Median · months
Time to Disease Progression (Initial Treatment)
monthsGemcitabine Plus DocetaxelDocetaxel Plus Capecitabine
Time to Disease Progression (Initial Treatment)9.28 (7.73 to 10.79)8.88 (7.37 to 11.05)
Statistical analysis
  • Gemcitabine Plus Docetaxel vs Docetaxel Plus Capecitabine · Log Rank · p = 0.385
SecondaryDuration of Response (Initial Treatment)

Among tumor responders, duration of tumor response was measured from the date of response (complete response \[CR\] or partial response \[PR\] until the first date of documented progression or death from any cause. Duration of response was censored at the earliest of: 1) date of last contact for participants alive without disease progression (DP); or 2) start date of other anti-tumor therapy for DP; or 3) dose date of crossover treatment.

Time frame:
Date of response (CR or PR) until the first date of documented progression or death from any cause (up to 82 months)
Reported as:
Median · months
Duration of Response (Initial Treatment)
monthsGemcitabine Plus DocetaxelDocetaxel Plus Capecitabine
Duration of Response (Initial Treatment)9.11 (7.60 to 11.94)10.39 (8.22 to 13.75)
Statistical analysis
  • Gemcitabine Plus Docetaxel vs Docetaxel Plus Capecitabine · Log Rank · p = 0.377
SecondaryDuration of Response (Crossover Treatment)

At crossover treatment, duration of response was measured from the time criteria were met for complete response (CR) or partial response (PR), until first date that recurrent or progressive disease was objectively documented or date of death due to any cause, whichever came first. This definition only applied to those who crossed over \& achieved CR or PR in crossover treatment. Duration of response censored at earliest of: 1) date of last contact for those alive without disease progression; or 2) start date of other anti-tumor therapy for documented disease progression.

Time frame:
Date of CR or PR until first date of recurrent or progressive disease after receiving crossover treatment was objectively documented or date of date due to any cause, whichever came first (up to 82 months)
Reported as:
Median · months
Duration of Response (Crossover Treatment)
monthsCapecitabineGemcitabine
Duration of Response (Crossover Treatment)25.89 (4.64 to 45.03)42.50 (16.02 to 48.22)
Statistical analysis
  • Capecitabine vs Gemcitabine · Log Rank · p = 0.446
SecondaryOverall Survival

Overall survival time was defined as the number of months between the date of randomization and the date of death due to any cause. The overall survival time was censored at the date of last contact for participants who were still alive.

Time frame:
Date of randomization to date of death from any cause (up to 82 months)
Reported as:
Median · months
Overall Survival
monthsGemcitabine Plus DocetaxelDocetaxel Plus Capecitabine
Overall Survival22.99 (18.82 to 25.69)23.29 (18.55 to 25.53)
Statistical analysis
  • Gemcitabine Plus Docetaxel vs Docetaxel Plus Capecitabine · Log Rank · p = 0.785
SecondaryBest Overall Response (Initial Treatment)

Best overall response was the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response was assessed using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that did not meet above criteria.

Time frame:
Best response from start of treatment until disease progression/recurrence (up to 82 months)
Reported as:
Number · participants
Best Overall Response (Initial Treatment)
participantsGemcitabine Plus DocetaxelDocetaxel Plus Capecitabine
Complete Response (confirmed)66
Partial Response (confirmed)7179
Stable Disease9690
Progressive Disease3227
Unknown3434
Statistical analysis
  • Gemcitabine Plus Docetaxel vs Docetaxel Plus Capecitabine · Fisher Exact · p = 0.364
SecondaryBest Overall Response (Crossover Treatment)

Best overall response was the best response recorded from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response assessed using RECIST criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that did not meet above criteria.

Time frame:
Best response from start of treatment until disease progression/recurrence (up to 82 months)
Reported as:
Number · participants
Best Overall Response (Crossover Treatment)
participantsCapecitabineGemcitabine
Complete Response (confirmed)11
Partial Response (confirmed)106
Stable Disease1920
Progressive Disease3436
Unknown1318
Statistical analysis
  • Capecitabine vs Gemcitabine · Fisher Exact · p = 0.446
SecondarySummary of Changes in Karnofsky Performance Status (KPS) by Treatment (Initial Treatment)

KPS ranges from 0 to 100, subdivided into three categories: incapacitated (0-40), self-care (50-70), and normal activity (80-100).

Time frame:
Baseline until crossover treatment began (up to 82 months)
Reported as:
Mean · units on a scale
Summary of Changes in Karnofsky Performance Status (KPS) by Treatment (Initial Treatment)
units on a scaleGemcitabine Plus DocetaxelDocetaxel Plus Capecitabine
Baseline90.85 ± 8.15990.09 ± 8.335
Change from Baseline-3.30 ± 9.259-3.27 ± 9.118
Statistical analysis
  • Gemcitabine Plus Docetaxel vs Docetaxel Plus Capecitabine · Mixed Models Analysis · p = 0.990
SecondarySummary of Changes in Karnofsky Performance Status (KPS) by Treatment (Crossover Treatment)

KPS ranges from 0 to 100, subdivided into three categories: incapacitated (0-40), self-care (50-70), and normal activity (80-100).

Time frame:
First day of crossover treatment until end of crossover treatment at trial discontinuation (up to 82 moths)
Reported as:
Mean · units on a scale
Summary of Changes in Karnofsky Performance Status (KPS) by Treatment (Crossover Treatment)
units on a scaleCapecitabineGemcitabine
Baseline89.09 ± 7.17487.94 ± 9.360
Change from Baseline-0.30 ± 7.839-1.27 ± 9.068
Statistical analysis
  • Capecitabine vs Gemcitabine · Mixed Models Analysis · p = 0.117
SecondarySummary of Changes in Rotterdam Symptom Checklist (RSCL) by Treatment (Initial Treatment)

RSCL includes 4 scales to assess quality of life (QOL) endpoints: 1) a 23-item physical distress level with scale score ranges from 23 to 92 \[low score represents better QOL\] 2)a 7-item psychological distress level with scale score ranges from 7 to 28\[low score represents better QOL\] 3)8-item activity level with scale score ranges from 8 to 32 \[high score represents better QOL\]; 1-item overall valuation of life with score range from 1 to 7 \[low score represents better QOL\].

Time frame:
Baseline until crossover treatment began (up to 82 months)
Reported as:
Mean · units on a scale
Summary of Changes in Rotterdam Symptom Checklist (RSCL) by Treatment (Initial Treatment)
units on a scaleGemcitabine Plus DocetaxelDocetaxel Plus Capecitabine
Baseline68.09 ± 25.10372.32 ± 23.693
Change from Baseline2.42 ± 27.093-2.68 ± 26.685
Statistical analysis
  • Gemcitabine Plus Docetaxel vs Docetaxel Plus Capecitabine · Mixed Models Analysis · p = 0.801
SecondarySummary of Changes in Rotterdam Symptom Checklist by Treatment (Crossover Treatment)

RSCL includes 4 scales to assess quality of life (QOL) endpoints: 1) a 23-item physical distress level with scale score ranges from 23 to 92 \[low score represents better QOL\] 2)a 7-item psychological distress level with scale score ranges from 7 to 28\[low score represents better QOL\] 3)8-item activity level with scale score ranges from 8 to 32 \[high score represents better QOL\]; 1-item overall valuation of life with score range from 1 to 7 \[low score represents better QOL\].

Time frame:
First day of crossover treatment until end of crossover treatment at trial discontinuation (up to 82 months)
Reported as:
Mean · units on a scale
Summary of Changes in Rotterdam Symptom Checklist by Treatment (Crossover Treatment)
units on a scaleCapecitabineGemcitabine
Baseline75.00 ± 20.87676.39 ± 17.663
Change from Baseline-2.78 ± 21.029-0.69 ± 27.133
Statistical analysis
  • Capecitabine vs Gemcitabine · Mixed Models Analysis · p = 0.190

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemcitabine Plus Docetaxel—72/237 (30.4%)233/237 (98.3%)
Docetaxel Plus Capecitabine—55/226 (24.3%)221/226 (97.8%)
Most frequent serious events
Showing 10 of 93
Most frequent serious events
EventGemcitabine Plus DocetaxelDocetaxel Plus Capecitabine
NeutropeniaBlood and lymphatic system disorders25/2377/226
Febrile neutropeniaBlood and lymphatic system disorders9/2379/226
LeukopeniaBlood and lymphatic system disorders6/2372/226
PyrexiaGeneral disorders4/2375/226
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/2370/226
DiarrhoeaGastrointestinal disorders2/2374/226
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders0/2374/226
Pericardial effusionCardiac disorders4/2370/226
VomitingGastrointestinal disorders4/2373/226
DehydrationMetabolism and nutrition disorders4/2372/226
Most frequent other events
Showing 10 of 54
Most frequent other events
EventGemcitabine Plus DocetaxelDocetaxel Plus Capecitabine
NeutropeniaBlood and lymphatic system disorders193/23773/226
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders15/237129/226
FatigueGeneral disorders129/237120/226
NauseaGastrointestinal disorders113/237118/226
DiarrhoeaGastrointestinal disorders111/237108/226
AnaemiaBlood and lymphatic system disorders113/23759/226
AlopeciaSkin and subcutaneous tissue disorders86/23798/226
Peripheral sensory neuropathyNervous system disorders78/23783/226
LeukopeniaBlood and lymphatic system disorders86/23725/226
VomitingGastrointestinal disorders71/23774/226

Baseline characteristics

Age Continuous
Age Continuous(years)Gemcitabine Plus DocetaxelDocetaxel Plus CapecitabineTotal
Mean55.8 ± 11.7754.6 ± 11.6055.2 ± 11.69
Sex: Female, Male
Sex: Female, Male(Participants)Gemcitabine Plus DocetaxelDocetaxel Plus CapecitabineTotal
Female2371238
Male2235237
Region of Enrollment
Region of Enrollment(participants)Gemcitabine Plus DocetaxelDocetaxel Plus CapecitabineTotal
United States173166339
Taiwan151833
Mexico141529
Puerto Rico415
Argentina111324
Brazil112
Australia111223
Korea, Republic of101020
Karnofsky Performance Status-Baseline
Karnofsky Performance Status-Baseline(units on a scale)Gemcitabine Plus DocetaxelDocetaxel Plus CapecitabineTotal
<=60 Needs increasing assistance up to Death (0)000
70 - Unable to carry on normal activity161531
80 - Activity with effort; some signs of disease444084
90 - Normal activity; minor signs of disease101101202
100 - Normal no complaints; no evidence of disease7475149
Missing459
Race/Ethnicity
Race/Ethnicity(participants)Gemcitabine Plus DocetaxelDocetaxel Plus CapecitabineTotal
Caucasian160158318
African Descent231235
Oriental283058
Hispanic263662
Other202
08

Study locations

65 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Glendale, Arizona, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Fort Smith, Arkansas, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Hot Springs, Arkansas, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Little Rock, Arkansas, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Springdale, Arkansas, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Berkeley, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Fountain Valley, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Highland, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    La Jolla, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Los Angeles, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Rancho Mirage, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    San Diego, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Santa Rosa, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Sylmar, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    Denver, Colorado, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    Torrington, Connecticut, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Fort Myers, Florida, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Hollywood, Florida, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    Orlando, Florida, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Idaho Falls, Idaho, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    South Bend, Indiana, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Iowa City, Iowa, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Louisville, Kentucky, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Metairie, Louisiana, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Royal Oak, Michigan, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Southfield, Michigan, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Columbia, Missouri, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    St. Louis, Missouri, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Fremont, Nebraska, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Voorhees, New Jersey, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    New York, New York, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Springfield, Ohio, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.c
    Dunmore, Pennsylvania, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Franklin, Pennsylvania, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Johnstown, Pennsylvania, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Kittanning, Pennsylvania, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Pittsburgh, Pennsylvania, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Charleston, South Carolina, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Knoxville, Tennessee, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Memphis, Tennessee, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Nashville, Tennessee, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Austin, Texas, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Dallas, Texas, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Lubbock, Texas, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    San Antonio, Texas, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Madison, Wisconsin, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Milwaukee, Wisconsin, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Capital Federal, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Mendoza, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rosario, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Santa Fe, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Waratah, New South Wales, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Redcliffe, Queensland, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Ashford, South Australia, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Porto Alegre, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Seoul, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Acapulco, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Mexico City, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Michoacan, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Toluca, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    San Juan, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Kaohsiung, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Taichung, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Taipei, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    Tao-Yuan, Taiwan
09

References and documents

Publications

  • Hoon SN, Lau PK, White AM, Bulsara MK, Banks PD, Redfern AD. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer. Cochrane Database Syst Rev. 2021 May 26;5(5):CD011220. doi: 10.1002/14651858.CD011220.pub2. PubMed 34037241 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2002, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Feb 2002
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Dec 8, 2009
Last update
Dec 24, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00191152
First posted
Sep 19, 2005
Start date
Feb 2002
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Dec 8, 2009
Last update
Dec 24, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine

Start the discussion